Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2025

Description

Chronic obstructive pulmonary disease (COPD) treatment encompasses medical interventions aimed at symptom management, progression mitigation, and overall quality of life improvement for individuals with COPD. COPD, characterized by airflow obstruction, chronic inflammation, and lung tissue damage, requires a comprehensive approach to medical care.

Key pharmaceutical interventions in chronic obstructive pulmonary disease (COPD) treatment include combination therapy, bronchodilators, corticosteroids, phosphodiesterase type 4 inhibitors, mucokinetics, and other drug classes. Combination therapy involves the administration of multiple therapies to address the complex nature of COPD. This approach entails providing patients with a range of tablets, each containing specific medications. Widely utilized in the treatment of conditions such as chronic bronchitis and emphysema, combination therapy is prevalent in healthcare settings, including hospitals, clinics, and homecare, as part of the COPD treatment regimen.

The chronic obstructive pulmonary disease (COPD) treatment market research report is one of a series of new reports from The Business Research Company that provides chronic obstructive pulmonary disease (COPD) treatment market statistics, including chronic obstructive pulmonary disease (COPD) treatment industry global market size, regional shares, competitors with a chronic obstructive pulmonary disease (COPD) treatment market share, detailed chronic obstructive pulmonary disease (COPD) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the chronic obstructive pulmonary disease (COPD) treatment industry. This chronic obstructive pulmonary disease (COPD) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic obstructive pulmonary disease (COPD) treatment market size has grown strongly in recent years. It will grow from$20.84 billion in 2024 to $21.94 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to smoking epidemic and tobacco use, advancements in inhalation therapies, awareness programs and early diagnosis, government initiatives for respiratory health, research and development in pulmonology

The chronic obstructive pulmonary disease (COPD) treatment market size is expected to see strong growth in the next few years. It will grow to $27.74 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to personalized medicine and biomarker research, biologic therapies and targeted interventions, air quality concerns and environmental factors, global efforts for smoking cessation, collaborations for drug development. Major trends in the forecast period include digital health solutions for COPD management, biologic therapies for COPD, emergence of personalized medicine, combination therapies and inhalers, early diagnosis and intervention, pulmonary rehabilitation programs.

The growth projections for the chronic obstructive pulmonary disease (COPD) treatment market are fueled by the increasing prevalence of lung disease, a condition that adversely impacts lung function. Lung diseases, including asthma, COPD, and lung cancer, are widespread, affecting millions globally. COPD treatment plays a crucial role in addressing lung diseases by managing symptoms, slowing disease progression, and preventing lung damage through the use of inhalers and medications. For example, as of September 2022, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) reported that 3.2 million people succumb to COPD annually, impacting approximately 200 million individuals. Additionally, the prevalence of asthma globally in 2022 reached 262 million people, and the LUNGevity Foundation projected that lung cancer would cause 127,000 annual deaths in the US alone by 2023. This increasing prevalence of lung diseases propels the growth of the COPD treatment market.

The trajectory of the chronic obstructive pulmonary disease (COPD) treatment market is further influenced by the rising prevalence of smoking. Smoking, involving the inhalation of smoke, particularly from burning substances such as tobacco, is a significant contributor to respiratory issues and COPD. Treatment for COPD is increasingly sought after by individuals who smoke, aiming to enhance breathing, improve quality of life, reduce exacerbations, enhance exercise tolerance, increase longevity, and improve mental health. As of July 2023, a report from The World Health Organization revealed that tobacco-related deaths exceed 8 million annually, with 1.3 million non-smokers affected by second-hand smoke inhalation. The escalating prevalence of smoking underscores the driving force behind the growth of the COPD treatment market.

A notable trend in the chronic obstructive pulmonary disease (COPD) treatment market is the emphasis on product innovation by major industry players. Companies operating in this market are actively engaged in the development of innovative products to strengthen their market position. For example, in April 2022, GlaxoSmithKline plc (GSK), a leading UK-based pharmaceutical and biotechnology company, introduced Trelegy Ellipta-a groundbreaking single-inhaler triple treatment (SITT) for patients with COPD in India. Trelegy Ellipta, comprising fluticasone furoate, umeclidinium, and vilanterol, serves as a maintenance medication for treating and preventing COPD symptoms in individuals aged 18 and older. The product's mechanism involves mimicking natural corticosteroid hormones, reducing immune system activity, and alleviating airway swelling for improved breathing.

Innovative product development continues to be a strategic focus for major companies in the COPD treatment market, exemplified by offerings such as Vilfuro-G. Launched by Lupin Limited, an India-based pharmaceutical company in November 2023, Vilfuro-G stands as the world's first fixed-dose triple combination medication (FDC) designed to effectively treat COPD. With a fixed, once-daily dosage, Vilfuro-G is expected to significantly enhance the lives of COPD patients, expanding Lupin's respiratory product line and showcasing the company's commitment to delivering cutting-edge treatment options. As the only FDC tailored to combine glycopyrronium bromide, vilanterol, and fluticasone furoate, Vilfuro-G addresses the long-term treatment and management of moderate to severe COPD.

In March 2023, a collaboration between UC Davis Health, a US-based health system, and Propeller Health, a US-based digital health company specializing in respiratory health, further exemplifies the trend of integrating digital health technologies into COPD treatment. This partnership aims to utilize Propeller's remote monitoring program, incorporating sensors, a mobile app, a web interface, and personalized support to deliver individualized treatment for high-risk patients with chronic respiratory illnesses such as asthma and COPD. This collaboration underscores a commitment to leveraging digital health solutions to enhance clinical outcomes and improve care for individuals with chronic conditions.

Major companies operating in the chronic obstructive pulmonary disease (COPD) treatment market include Almirall S.A., AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Abbott Laboratories, Chiesi Farmaceutici S.p.A, Mylan N.V., Orion Corporation, Sunovion Pharmaceuticals Inc., Dr. Reddy's Laboratories Ltd., Circassia Group PLC, Kyowa Kirin Co. Ltd., Sanofi S.A, Theravance Biopharma Inc., Verona Pharmaceuticals plc, Alcon Laboratories Inc., Amgen Inc., Apotex Inc., Aurobindo Pharma Limited, Biocon Limited, Biogen Inc., Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals plc, Lupin Limited, Meda AB, Mundipharma International Limited, Pfizer Inc.

North America was the largest region in the chronic obstructive pulmonary disease (COPD) treatment market in 2024. Asia-Pacific is expected to be the global chronic obstructive pulmonary disease (COPD) treatment market report during the fastest-growing region in the forecast period. The regions covered in the chronic obstructive pulmonary disease (copd) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the chronic obstructive pulmonary disease (copd) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The chronic obstructive pulmonary disease (COPD) treatment market includes revenues earned by entities by providing services such as oxygen therapy, pulmonary rehabilitation, medication services, endobronchial valve therapy and non-invasive ventilation services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic obstructive pulmonary disease (copd) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic obstructive pulmonary disease (copd) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic obstructive pulmonary disease (copd) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: Combination Therapy; Bronchodilators; Corticosteroids; Phosphodiesterase Type 4 Inhibitor; Mucokinetics; Other Drug Classes
2) By Type: Chronic Bronchitis; Emphysema
3) By End-User: Hospitals; Clinics; Homecare Settings
Subsegments:
1) By Combination Therapy: Long-Acting Beta-Agonists (LABA) + Inhaled Corticosteroids (ICS); Long-Acting Muscarinic Antagonists (LAMA) + LABA; Triple Therapy (LAMA + LABA + ICS)
2) By Bronchodilators: Short-Acting Beta-Agonists (SABA); Long-Acting Beta-Agonists (LABA); Long-Acting Muscarinic Antagonists (LAMA)
3) By Corticosteroids: Inhaled Corticosteroids (ICS); Oral Corticosteroids; Injectable Corticosteroids
4) By Phosphodiesterase Type 4 Inhibitor: Roflumilast; Other PDE4 Inhibitors
5) By Mucokinetics: Expectorants; Mucolytics
6) By Other Drug Classes: Antibiotics; Antivirals; Antifungal Agents
Companies Mentioned: Almirall S.A.; AstraZeneca plc; Boehringer Ingelheim International GmbH; F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r24023

1. Executive Summary

2. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Characteristics

3. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Trends And Strategies

4. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Growth Analysis And Strategic Analysis Framework

5.1. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Growth Rate Analysis
5.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Total Addressable Market (TAM)

6. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Segmentation

6.1. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Combination Therapy
Bronchodilators
Corticosteroids
Phosphodiesterase Type 4 Inhibitor
Mucokinetics
Other Drug Classes
6.2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chronic Bronchitis
Emphysema
6.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Homecare Settings
6.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Long-Acting Beta-Agonists (LABA) + Inhaled Corticosteroids (ICS)
Long-Acting Muscarinic Antagonists (LAMA) + LABA
Triple Therapy (LAMA + LABA + ICS)
6.5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Sub-Segmentation Of Bronchodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Short-Acting Beta-Agonists (SABA)
Long-Acting Beta-Agonists (LABA)
Long-Acting Muscarinic Antagonists (LAMA)
6.6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Inhaled Corticosteroids (ICS)
Oral Corticosteroids
Injectable Corticosteroids
6.7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Sub-Segmentation Of Phosphodiesterase Type 4 Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Roflumilast
Other PDE4 Inhibitors
6.8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Sub-Segmentation Of Mucokinetics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Expectorants
Mucolytics
6.9. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antibiotics
Antivirals
Antifungal Agents

7. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Regional And Country Analysis

7.1. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

8.1. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

9.1. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
9.2. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

10.1. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

11.1. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
11.2. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

12.1. Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

13.1. Indonesia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

14.1. South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
14.2. South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

15.1. Western Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
15.2. Western Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

16.1. UK Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

17.1. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

18.1. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

19.1. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

20.1. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

21.1. Eastern Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
21.2. Eastern Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

22.1. Russia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

23.1. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
23.2. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

24.1. USA Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
24.2. USA Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

25.1. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
25.2. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

26.1. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
26.2. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

27.1. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

28.1. Middle East Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
28.2. Middle East Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

29.1. Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Overview
29.2. Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Competitive Landscape And Company Profiles

30.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Competitive Landscape
30.2. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Company Profiles
- 30.2.1. Almirall S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Other Major And Innovative Companies

31.1. Novartis AG
31.2. Teva Pharmaceutical Industries Ltd.
31.3. Astellas Pharma Inc.
31.4. Abbott Laboratories
31.5. Chiesi Farmaceutici S.p.A
31.6. Mylan N.V.
31.7. Orion Corporation
31.8. Sunovion Pharmaceuticals Inc.
31.9. Dr. Reddy's Laboratories Ltd.
31.10. Circassia Group PLC
31.11. Kyowa Kirin Co. Ltd.
31.12. Sanofi S.A
31.13. Theravance Biopharma Inc.
31.14. Verona Pharmaceuticals plc
31.15. Alcon Laboratories Inc.

32. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

34. Recent Developments In The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

35. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market High Potential Countries, Segments and Strategies

35.1 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market In 2029 - Countries Offering Most New Opportunities
35.2 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market In 2029 - Segments Offering Most New Opportunities
35.3 Chronic Obstructive Pulmonary Disease (COPD) Treatment Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer